Encouraging moderation, balance and real-life engagement coupled with education may combat the overuse of wireless mobile devices and subsequent adverse health outcomes, according to research being presented Sunday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
The accurate diagnosis of prediabetes in the primary care setting might depend on a patient’s age, BMI, gender, race and certain comorbidities, according to research being presented at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
The diabetes drug empagliflozin may decrease the risk of kidney stones in patients with type 2 diabetes, according to a new study presented Sunday, June 12 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Women who are longer-term survivors of metastatic breast cancer may have a worse survival rate if they have diabetes and poorly controlled blood sugar levels, according to a new study presented Sunday, June 12 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Male runners who do not receive enough energy from their diet may be at risk for stress fractures, according to a new study presented Saturday, June 11 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
A new study conducted by Vertice Pharma confirms the absorption of an oral levothyroxine sodium solution (Thyquidity® 100g/ 5mL) was not affected by consuming coffee 5 minutes after the dose, according to research being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
The cost of mental health disorders associated with polycystic ovary syndrome (PCOS) – depression, anxiety and eating disorders – reached almost $6 billion in 2021, according to a new study presented Monday, June 13 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Probiotic bacteria may enhance anti-cancer activities of the breast cancer drug tamoxifen and other endocrine-targeted therapies, which could help reduce the risk of estrogen receptive positive (ER+) breast cancer, suggests a new study presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
For the first time in the last 30 years, the consumption of ultra-processed foods among teenagers in the United States declined during the COVID-19 pandemic, according to a new study presented at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Inactivated and mRNA COVID-19 vaccines appear to be safe for patients treated for hypothyroidism, according to a new study being presented at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga. The study found these vaccines do not cause significant fluctuations in thyroid function and are not associated with increased risks of emergency department visits or unscheduled hospitalizations.
There is a greater prevalence of obesity and higher body fat among people who face food insecurity, according to research being presented Sunday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Testosterone replacement therapy improved sexual symptoms, libido, symptom severity, delayed verbal recall and overall quality of life among people with poorly controlled type 2 diabetes and hypogonadism, according to research being presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Growth hormone deficiency (GHD) among adults is associated with greater medical costs and an increased rate of other health conditions compared with those without GHD, according to industry-sponsored research being presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Two experimental male contraceptive pills appear to effectively lower testosterone without causing unacceptable side effects, according to a new study that will be presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Prediabetes appears to be a strong independent risk factor for heart attacks, according to a new study presented Saturday, June 11 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
An investigative stem cell-based therapy called PEC-Direct, designed to act as a replacement pancreas, has the potential to provide blood sugar control in patients with high-risk type 1 diabetes, suggests a clinical study presented Saturday, June 11 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Patients with type 2 diabetes have an increased risk for fractures, despite their normal-to-high bone mineral density, according to research being presented Saturday, June 11 at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Fezolinetant significantly reduced the frequency and severity of moderate-to-severe vasomotor symptoms (VMS), or hot flashes, associated with menopause, according to a Phase 3 industry-sponsored study being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
Women with obesity, even those with regular menstrual cycles, have suppressed ovarian follicle development and reduced production of reproductive hormones, which may underlie reduced fertility, according to a new study being presented Saturday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga.
An investigational drug taken while undergoing chemotherapy demonstrated superior overall survival compared to chemotherapy alone in adult patients with a common, highly aggressive subtype of acute myeloid leukemia (AML).
Investigators from Cedars-Sinai will present the latest novel stem cell and regenerative medicine research at the International Society for Stem Cell Research (ISSCR) Annual Meeting, which is being held in person and virtually June 15-19 in San Francisco.
A simple diagnostic procedure, followed by an interventional radiology treatment known as fallopian tube recanalization, could allow a high percentage of women struggling with infertility from blocked fallopian tubes to conceive with less involved or, in some cases, no further invasive fertility procedures, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting.
Previous clinical trials have provided insufficient evidence to decide whether testosterone causes heart problems in men during the first year of treatment, according to research being presented Monday at ENDO 2022, the Endocrine Society’s annual meeting in Atlanta, Ga., and published in The Lancet Healthy Longevity.
The American Society of Retina Specialists (ASRS) invites members of the press to cover the latest advances in retina science and practice during its 40th Annual Scientific Meeting, July 13-16.
Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, presented results of the MOMENTUM phase 3 randomized study, which evaluated momelotinib against a second medication, danazol, in symptomatic and anemic MF patients previously treated with standard-of-care JAK inhibitor therapy.
New research led by Kara Kelly, MD, of Roswell Park Comprehensive Cancer Center and presented today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago shows that a combination of brentuximab vedotin (Bv) and standard chemotherapy is safe and more effective than standard chemotherapy in pediatric patients up to age 21 years with newly diagnosed high-risk Hodgkin lymphoma. The findings from a phase 3 National Cancer Institute-supported multicenter Children’s Oncology Group clinical trial (NCT 02166463) were presented by first author Sharon Castellino, MD, of Emory University and Children’s Healthcare of Atlanta in an oral abstract session on Friday, June 3.
Results from three early-stage clinical trials led by researchers at The University of Texas MD Anderson Cancer Center show promising activity with novel immunotherapies and targeted therapies for patients with advanced tumors.
Press materials are now available for NUTRITION 2022 LIVE ONLINE, the flagship annual meeting of the American Society for Nutrition (ASN).
Dietary guidelines form the basis for nutrition advice and regulations around the world. While there is strong scientific consensus around most existing guidelines, one question has recently stirred debate: Should consumers be warned to avoid ultra-processed foods?
McMaster researchers tracked 501 patients with luminal A breast cancer for five years post-surgery and found the recurrence of cancer in the breast was just 2.3 per cent without radiotherapy. This was roughly comparable with a 1.9 per cent risk this patient sample had of developing a new breast cancer in their other untreated breast.
Long-term exposure to air pollution is linked to a greater risk of severe COVID-19, new research being presented at Euroanaesthesia, the annual meeting of the European Society of Anaesthesiology and Intensive Care (ESAIC) in Milan, Italy (4-6 June), finds.
Babies born to mothers who suffered COVID-19 disease during pregnancy seem to exhibit differences in neurodevelopmental outcomes at 6 weeks, according to a preliminary analysis presented in the 30th European Congress of Psychiatry.
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of the gut microbiome as a targetable biomarker to improve responses to immunotherapy were presented today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.
On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML), in a talk at the American Society of Clinical Oncology (ASCO) annual meeting 2022.
At this year’s European Alliance of Associations for Rheumatology (EULAR) Congress, held June 1 to 4 in Copenhagen, Hospital for Special Surgery (HSS) presented new research related to the treatment and management of rheumatoid arthritis (RA). The studies focus on the tapering of treatment in patients whose disease is well controlled, real-world outcomes for targeted therapies, assessing the effects of biologic treatments on immune cells from patients with RA, and the underlying mechanisms of arthritis triggered by immune checkpoint therapies used to treat cancer.
Promising clinical results with cellular therapies for patients with blood cancers highlight advances being presented by researchers from The University of Texas MD Anderson Cancer Center at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. These findings include long-term outcomes of patients receiving an infusion of brexucabtagene autoleucel (KTE-X19) for mantle cell lymphoma, efficacy of gamma delta CAR T therapy for aggressive B-cell lymphoma and responses of umbilical cord blood-derived expanded natural killer cells when given together with combination therapy before stem cell transplant.
Patients with multiple myeloma who have been treated with a three-drug combination therapy have a growing number of choices for subsequent treatment. Results of a new study led by researchers at Dana-Farber Cancer Institute can help patients and their physicians weigh benefits and risks of each option.
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting.
A multi-institutional, international study, led by researchers at the Johns Hopkins Kimmel Cancer Center and WEHI in Melbourne, Australia, found that testing for ctDNA after surgery and directing chemotherapy to ctDNA-positive patients reduced the use of chemotherapy overall without compromising recurrence-free survival.
Results of a Phase II clinical trial led by Cedars-Sinai Cancer investigators indicate that an immunotherapy drug combination could extend the lives of those diagnosed with advanced non-small cell lung cancer, one of the most common forms of lung cancer. The research was presented today during the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, with simultaneous publication in the peer-reviewed Journal of Clinical Oncology.
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions in the brain that metastasized from the lung tumors, according to results of a study led by Dana-Farber Cancer Institute investigators.
Eduardo Bruera, M.D., chair of Palliative Care Medicine at The University of Texas MD Anderson Cancer Center, has received the American Society of Clinical Oncology (ASCO) Walther Cancer Foundation Supportive Oncology Award. Bruera was formally recognized today at the 2022 ASCO Annual Meeting during the Mentorship and Career Development Roundtable.
Physicians and scientists from Cedars-Sinai will discuss the latest advances in treatment, care and research at the Endocrine Society’s annual meeting (ENDO 2022) in Atlanta, June 11-14.
The knowledge a medical physicist brings to treatment plans for patients usually focuses on science and technology. But more and more, these scientists are taking the lead on a people-first approach to better health care for those who need it. During the President's Symposium at the annual AAPM meeting, three keynote speakers will discuss treatment of the Alzheimer's epidemic, the dynamics of patient engagement, and two research initiatives prioritized by the Biden administration.
A new study led by Hospital for Special Surgery (HSS) investigators in New York City has found that their computer vision tool effectively distinguishes rheumatoid arthritis (RA) from osteoarthritis (OA) in joint tissue taken from patients who underwent total knee replacement (TKR). The results suggest the machine learning model will help improve research processes in the short term and optimize patient care in the future. The findings were presented today at the European Alliance of Associations for Rheumatology (EULAR) Congress 2022.
Combination chemoimmunotherapy with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. The study results also were published today in the New England Journal of Medicine.
Below are summaries of recent Fred Hutchinson Cancer Center research findings and other news.
A new study by researchers at Hospital for Special Surgery (HSS) has further clarified the clinical manifestations of undifferentiated connective tissue disease (UCTD). The findings were published as an abstract in the meeting journal of the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress.
A study that includes researchers at Hospital for Special Surgery (HSS) underscores the importance of a multidisciplinary medical team to counsel and provide care for women with systemic lupus erythematosus, the most common form of lupus, who become pregnant. Using a nationwide database, the investigators reviewed the records of more than 50,000 patients with lupus who gave birth over a 10-year period. Findings revealed a higher rate of fetal morbidity and severe maternal morbidity compared to women who did not have lupus.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right